Avasarala, J. (2017) “Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill”, Drug Target Insights, 11(1). doi: 10.33393/dti.2017.1367.